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| INTRODUC TI ON
Severe haemophilia A (HA) and haemophilia B (HB; factor levels <0.01 IU/mL 1 ) are characterised by spontaneous joint and muscle bleeding 2, 3 and represent approximately 30% of haemophilia cases in Europe. 3, 4 Patients with severe haemophilia experience acute pain and joint stiffness during bleeds, with recurrent bleed events leading to chronic synovitis and diminished range of movement (ROM) in the affected joint. Approximately 90% of patients will develop chronic haemophilic arthropathy, associated with chronic pain, disability and impaired health-related quality of life (HRQoL), by 30 years of age. 5, 6 There has been a perception that HB is associated with less severe clinical symptoms than HA, and that patients with HA have worse HRQoL when compared with HB. [7] [8] [9] In 2009, Tagariello et al 10 showed that patients with HA had a threefold greater risk of undergoing orthopaedic arthroplasty. Lower rates of prophylaxis use and overall factor concentrate consumption have been used to support the notion that HB is less severe than HA. 11, 12 Recently, it was reported in an Italian cohort of 105 patients that the proportion with a high incidence (>50) of haemarthroses across their lifetime was greater in HA compared with HB. 13 A suggested explanation for the clinical symptoms in patients with HB being milder than HA may be genetic factors that are still poorly understood. 8 However, this clinical perception of the differences between the severity of clinical findings and HRQoL in HA and HB remains to be supported or refuted within a single research cohort.
Recently, the findings from a cross-sectional, retrospective study, the Cost of Haemophilia in Europe: a Socioeconomic Survey (CHESS) was reported. 14 The CHESS study evaluated the annual economic and psychosocial burden of severe haemophilia A and B, in patients sampled from five European countries. Using data from the CHESS study, this study aimed at comparing the annual bleeding rate (ABR), reporting of target joints and HRQoL between patients with HA and HB. 
| MATERIAL SANDME THODS

| Patientdatasource:theCHESSstudy
| Annualbleedingrate(ABR)
Bleeding frequency was reported in this study as a combination of annual major and minor bleeding rates, derived from patient records, 
| Targetjoints
A "target joint" as defined in the CHESS study encompasses any joint with known chronic synovitis. To incorporate the nuanced definitions and diagnostic options that exist within registries, trials and guidelines, 17 study investigators were given discretion as to any further criteria they might use to define target joints with respect to bleed frequency and period of observation.
| Health-relatedqualityoflife(HRQoL)
Health-related quality of life for patients in the CHESS study was assessed using the three-level version (no problems, some problems and extreme problems) of the EQ-5D patient questionnaire covering the following five dimensions: self-care, mobility, usual daily activities, pain/discomfort and anxiety/depression. 18, 19 A single weighted index score is derived through an amalgam of the five dimensions, with index scores anchored at 0 (dead) and 1 (perfect health), though scores of less than zero ("worse than dead") can also be derived.
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The EQ-5D questionnaire was chosen for this study because it provided a validated method for measuring health status as shown in the recently reported findings of the CHESS study. 14,18,19 Health status as described by the EQ-5D visual analogue scale (VAS), a 0-100 scale of the patient's perception of their current health (0 = the worst health the respondent can imagine; 100 = the best health state), is also shown in the descriptive analysis.
| Statisticalanalysis
Descriptive analysis was used to summarize patient clinical characteristics. The mean and standard deviation (SD) were used for data and frequency analysis. Standard t tests and Pearson's chi-squared test were used for between-group differences between data on HA and HB, including for ABRs, the presence of one or more target joints and EQ-5D index scores.
Multivariate models were constructed to determine whether haemophilia type (ie HA or HB) was a statistically significant predictor of ABR, target joints or HRQoL when controlling for additional covariates linked to these clinical outcomes. A generalized linear model (GLM) was used to specify the ABR and HRQoL (ie EQ-5D
index scores) models, 21 while multivariate logistic regression model was used to assess the relationship with the presence of target joints.
Age and body mass index (BMI) were included as covariates in all three models; additional covariates in the ABR and target joint models were current treatment strategy (primary/secondary prophylaxis/on demand) and history of inhibitor detection (never/once/ more than once). Physician-reported therapy adherence as measured on a 1-3 scale (full, partial, none) was included as a further covariate in the ABR model. Additional covariates in the EQ-5D model were HCV/HIV seropositivity, physician-reported chronic pain using the pain component of the WFH Physical Examination Score (Gilbert score). 16 To avoid censoring data, for prediction of EQ-5D index scores, the index score value Y was transformed using nY = 1 − Y and results reported as EQ-5D disutility. The final value output was the average marginal effect of HA and HB on ABRs, target joints and EQ-5D
index score, expressed as additionally recorded bleeds and target joints per year, and disutility, respectively.
| RE SULTS
| Populationcharacteristics
Of the 1227 patients studied, 77% (n = 949) had HA (mean age, 35 years) and 23% (n = 278) had HB (mean age, 36 years; Table 1 ).
The proportion of patients with inhibitors was similar for haemophilia A and haemophilia B; this may be a chance occurrence or possibly the result of clinical practice in the participating countries. There were slightly fewer HB patients receiving prophylaxis compared with HA (54% vs 58%), but this difference was not statistically significant (P = 0.194). Two patients were excluded from the ABR analysis due to physician responses written as proportions (%) of minor vs major bleeds (sum of bleeds = 100). Patient record data were available for all patients on target joints. Of the 514 patients who completed the EQ-5D, 78% (n = 404) had HA, and 22% (n = 110) had HB.
| Unadjustedcomparisonofclinical outcomesandhealthstatus
The mean ABR was significantly greater in HB patients (4.6 ± 5.8) compared with HA (3.8 ± 4.4; P = 0.015; Table 2 ). However, the proportion of patients reporting 10 or more bleeds in the previous year (10% and 13% for HA and HB, respectively) was not significantly higher in HB. There were no significant differences between HA and HB with regard to the proportion of patients with ≥1 target joints (59% and 54% for HA and HB, respectively; P = 0.104) nor the mean number of target joints affected (1.15 ± 1.37 vs 0.99 ± 1.33;
Of the 514 patients who completed the EQ-5D questionnaire, the mean EQ-5D index score for patients with HA (0.78 ± 0.26) and TA B L E 2 ABR and target joint status of the 1225 patients with severe haemophilia A and B (HA and HB) HB (0.76 ± 0.29) was similar ( Table 3) . A positive association between HB and the self-care domain of the EQ-5D was observed, with 77% and 82% of HA and HB patients reporting no problems, respectively (P = 0.048).
| Multivariateregression
The average mean effect (AME) of model covariates on ABR is shown in Table 4 . Positive associations with ABR were BMI (AME = 0.07, 0.01-0.13) and history of an inhibitor (either once [AME = 1.40, 0.29-2.51] or more than once [AME = 3.48, 0.29-6.68]). Primary prophylaxis (AME = −2.24, −2.89 to −1.60) was negatively associated with ABR. Haemophilia type had no significant marginal effect on ABR (AME = 0.23, −0.38-0.84).
Adjusted odds ratios (aORs) of the model predictors on the presence of a target joint are shown in Table 5 . The average mean effect of model covariates on EQ-5D index scores is shown in Table 6 . Positive associations with EQ-5D were age (AME = 0.00, 0.00-0.01) and any nonzero level of chronic pain (mild: AME = 0.14, 0.06-0.22; moderate: AME = 0.25, 0.15-0.36; severe: AME = 0.71, 0.32-1.11). Haemophilia type had no significant marginal effect on EQ-5D index scores (AME = 0.04, −0.06-0.13).
| D ISCUSS I ONANDCON CLUS I ON
This study compared the ABR and HRQoL between patients with HA and HB using recent data from the Cost of Haemophilia in Europe: a Socioeconomic Survey (CHESS) study. 14 Severe problems 17 (4) 8 (7) SD, standard deviation; VAS, visual analogue scale. a n = 511.
*P value is calculated by independent t test or Pearson's chi-squared test.
TA B L E 3 EQ-5D index scores and domain responses of the 514 patients with severe haemophilia A and B (HA and HB)
promote the same standard of prophylaxis treatment for patients with HA and HB are warranted. 17, [22] [23] [24] [25] [26] [27] The difference in clinical severity of severe HB compared with HA has long been a topic of controversy, with some studies indicating that HB had less impact on HRQoL, with lower rates of bleeding, less joint damage and reduced requirement for surgical joint treatment. 7, 8, 10, 13 However, the findings of this study have shown that although HB is less prevalent than HA, both HA and HB have important clinical and HRQoL impacts on patients: including the effects of bleeding into target joints, that results in pain; long-term effects, such as reduced range of movement (ROM), with up to 90% of patients developing chronic arthropathy due to haemophilia by 30 years of age. 5, 6 In addition, results of the multivariate analysis indicated that BMI, previous history of an inhibitor and primary prophylaxis regi- TA B L E 6 Regression analysis for EQ-5D disutility using a generalized linear model (GLM) AME (95% CI), average marginal effect and 95% confidence interval.
